Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Barnes & Noble Education, Inc.BNED · Entity 5624 | Director | September 24, 2021 | September 27, 2021 |
| PhenixFIN CorpPFX · Entity 6843 | Director | September 16, 2025 | September 18, 2025 |
| iMedia Brands, Inc.EVLV · Entity 12386 | Director | June 28, 2017 | June 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Barnes & Noble Education, Inc.
Report date September 24, 2021 · Filed September 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,585 |
Reported balance
After 2021-09-24 transaction · row 1
1 source rowRow 1 · 2021-09-24 · Grant · Acquired 11,804 · Balance 60,585 F1: Grant of restricted shares vesting on September 24, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted shares vesting on September 24, 2022.
PhenixFIN Corp
Report date September 16, 2025 · Filed September 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, $0.001 par valueSEC Table I · non-derivative | Direct | 3,000 |
Ending reported balance
After 2025-09-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-09-16 · Purchase · Acquired 86 · Balance 2,956 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.05 to $48.10, inclusive. The reporting person undertakes to provide to PhenixFIN Corporation, any security holder of PhenixFIN Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Row 2 · 2025-09-17 · Purchase · Acquired 44 · Balance 3,000 F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.15 to $48.27, inclusive. The reporting person undertakes to provide to PhenixFIN Corporation, any security holder of PhenixFIN Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.05 to $48.10, inclusive. The reporting person undertakes to provide to PhenixFIN Corporation, any security holder of PhenixFIN Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.15 to $48.27, inclusive. The reporting person undertakes to provide to PhenixFIN Corporation, any security holder of PhenixFIN Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4.
iMedia Brands, Inc.
Report date June 28, 2017 · Filed June 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 138,165 |
Reported balance
After 2017-06-28 transaction · row 1
1 source rowRow 1 · 2017-06-28 · Purchase · Acquired 7,000 · Balance 138,165 |
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARATANA THERAPEUTICS, INC.
Report date July 18, 2019 · Filed July 18, 2019
Section 16 reporting ended · disclosed 2019-07-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 1
1 source rowRow 1 · 2019-07-18 · Disposition to issuer · Disposed 4,500 · Balance 0 F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.34 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 | Direct | 0 |
Reported balance
After 2019-07-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2)
F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration").
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards.
F4: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares.
Cyxtera Technologies, Inc.
Report date July 29, 2021 · Filed August 02, 2021
Section 16 reporting ended · disclosed 2021-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2021-07-29 transaction · row 1
1 source rowRow 1 · 2021-07-29 · Exercise / conversion · Acquired 30,000 · Balance 30,000 F1: Represents shares of Class B common stock of Starboard Value Acquisition Corp. that converted into shares of Class A common stock of Cyxtera Technologies, Inc. (f/k/a Starboard Value Acquisition Corp.) (the "Issuer") in connection with the business combination between the Issuer, Mundo Merger Sub 1, Inc., Mundo Merger Sub 2, LLC, Cyxtera Technologies, Inc., and Mundo Holdings, Inc. F2: The reported number of shares reflect the receipt of 5,000 shares of Class B common stock of Starboard Value Acquisition Corp. as part of an in-kind dividend distributed to all holders of Class B common stock in connection with the closing of Starboard Value Acquisition Corp.'s initial public offering. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-07-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-29 · Exercise / conversion · Disposed 30,000 · Balance 0 F1: Represents shares of Class B common stock of Starboard Value Acquisition Corp. that converted into shares of Class A common stock of Cyxtera Technologies, Inc. (f/k/a Starboard Value Acquisition Corp.) (the "Issuer") in connection with the business combination between the Issuer, Mundo Merger Sub 1, Inc., Mundo Merger Sub 2, LLC, Cyxtera Technologies, Inc., and Mundo Holdings, Inc. F2: The reported number of shares reflect the receipt of 5,000 shares of Class B common stock of Starboard Value Acquisition Corp. as part of an in-kind dividend distributed to all holders of Class B common stock in connection with the closing of Starboard Value Acquisition Corp.'s initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Class B common stock of Starboard Value Acquisition Corp. that converted into shares of Class A common stock of Cyxtera Technologies, Inc. (f/k/a Starboard Value Acquisition Corp.) (the "Issuer") in connection with the business combination between the Issuer, Mundo Merger Sub 1, Inc., Mundo Merger Sub 2, LLC, Cyxtera Technologies, Inc., and Mundo Holdings, Inc.
F2: The reported number of shares reflect the receipt of 5,000 shares of Class B common stock of Starboard Value Acquisition Corp. as part of an in-kind dividend distributed to all holders of Class B common stock in connection with the closing of Starboard Value Acquisition Corp.'s initial public offering.
SITO MOBILE, LTD.
Report date June 01, 2017 · Filed June 02, 2017
Section 16 reporting ended · disclosed 2017-06-02. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2025 Filed Sep 18, 2025 21:35 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 44 | $48.26 | $2,123.44 |
DisclosureSEC source: 0001213900-25-089089 · ownership.xml · nonDerivative · entry 2 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.15 to $48.27, inclusive. The reporting person undertakes to provide to PhenixFIN Corporation, any security holder of PhenixFIN Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 21:35 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 86 | $48.09 | $4,135.74 |
DisclosureSEC source: 0001213900-25-089089 · ownership.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,956 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.05 to $48.10, inclusive. The reporting person undertakes to provide to PhenixFIN Corporation, any security holder of PhenixFIN Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 22:38 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 100 | $48.09 | $4,809.00 |
DisclosureSEC source: 0001213900-25-087773 · ownership.xml · nonDerivative · entry 2 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,870 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.05 to $48.10, inclusive. The reporting person undertakes to provide to PhenixFIN Corporation, any security holder of PhenixFIN Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 22:38 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 162 | $48.05 | $7,784.10 |
DisclosureSEC source: 0001213900-25-087773 · ownership.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,770 Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 21:35 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 34 | $48.05 | $1,633.70 |
DisclosureSEC source: 0001213900-25-086911 · ownership.xml · nonDerivative · entry 2 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,608 Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:35 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 250 | $48.17 | $12,042.50 |
DisclosureSEC source: 0001213900-25-086911 · ownership.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,574 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.15 to $48.20, inclusive. The reporting person undertakes to provide to PhenixFIN Corporation, any security holder of PhenixFIN Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 20:43 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 49 | $48.15 | $2,359.35 |
DisclosureSEC source: 0001213900-25-085571 · ownership.xml · nonDerivative · entry 2 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,324 Read SEC document |
| September 03, 2025 Filed Sep 8, 2025 20:43 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 100 | $48.23 | $4,823.00 |
DisclosureSEC source: 0001213900-25-085571 · ownership.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,275 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.00 to $48.75, inclusive. The reporting person undertakes to provide to PhenixFIN Corporation, any security holder of PhenixFIN Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| August 20, 2025 Filed Aug 21, 2025 19:26 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 75 | $49.28 | $3,696.00 |
DisclosureSEC source: 0001213900-25-079332 · ownership.xml · nonDerivative · entry 2 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,175 Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 19:26 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 189 | $49.25 | $9,308.25 |
DisclosureSEC source: 0001213900-25-079332 · ownership.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,100 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $49.10 to $49.27, inclusive. The reporting person undertakes to provide to PhenixFIN Corporation, any security holder of PhenixFIN Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:49 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 100 | $49.03 | $4,903.00 |
DisclosureSEC source: 0001213900-25-077974 · ownership.xml · nonDerivative · entry 3 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,911 Read SEC document |
| August 15, 2025 Filed Aug 18, 2025 20:49 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 15 | $48.87 | $733.05 |
DisclosureSEC source: 0001213900-25-077974 · ownership.xml · nonDerivative · entry 2 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,811 Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:49 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 132 | $48.90 | $6,454.14 |
DisclosureSEC source: 0001213900-25-077974 · ownership.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,796 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.70 to $49.25, inclusive. The reporting person undertakes to provide to PhenixFIN Corporation, any security holder of PhenixFIN Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| August 12, 2025 Filed Aug 12, 2025 21:04 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 36 | $49.13 | $1,768.68 |
DisclosureSEC source: 0001213900-25-075060 · ownership.xml · nonDerivative · entry 3 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,664 Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 21:04 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 101 | $49.13 | $4,962.13 |
DisclosureSEC source: 0001213900-25-075060 · ownership.xml · nonDerivative · entry 2 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,628 Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 21:04 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCOMMON STOCK, $0.001 par value | 27 | $49.00 | $1,323.00 |
DisclosureSEC source: 0001213900-25-075060 · ownership.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,527 Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 20:23 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCommon Stock, $0.001 par value | 100 | $48.90 | $4,890.25 |
DisclosureSEC source: 0001140361-25-004262 · form4.xml · nonDerivative · entry 2 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.86 to $48.95, inclusive. The reporting person undertakes to provide to PhenixFIN Corporation, any security holder of PhenixFIN Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 20:23 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCommon Stock, $0.001 par value | 400 | $48.79 | $19,515.40 |
DisclosureSEC source: 0001140361-25-004262 · form4.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,400 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.25 to $49.00, inclusive. The reporting person undertakes to provide to PhenixFIN Corporation, any security holder of PhenixFIN Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 21:59 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCommon Stock, $0.001 par value | 350 | $40.08 | $14,028.00 |
DisclosureSEC source: 0000922423-22-000014 · form4.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCommon Stock, $0.001 par value | 500 | $39.75 | $19,875.00 |
DisclosureSEC source: 0001140361-22-005815 · form4.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650 Read SEC document |
| September 24, 2021 Filed Sep 27, 2021 17:19 UTC | Barnes & Noble Education, Inc. BNED · Entity 5624 | GrantCommon Stock | 11,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001634117-21-000110 · wf-form4_163277755211271.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,585 F1 · shares: Grant of restricted shares vesting on September 24, 2022. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 21:36 UTC | Cyxtera Technologies, Inc. CYXT · Entity 112555 | Exercise / conversionClass B Common Stock · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031166 · doc4.xml · derivative · entry 2 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares of Class B common stock of Starboard Value Acquisition Corp. that converted into shares of Class A common stock of Cyxtera Technologies, Inc. (f/k/a Starboard Value Acquisition Corp.) (the "Issuer") in connection with the business combination between the Issuer, Mundo Merger Sub 1, Inc., Mundo Merger Sub 2, LLC, Cyxtera Technologies, Inc., and Mundo Holdings, Inc. F2 · shares: The reported number of shares reflect the receipt of 5,000 shares of Class B common stock of Starboard Value Acquisition Corp. as part of an in-kind dividend distributed to all holders of Class B common stock in connection with the closing of Starboard Value Acquisition Corp.'s initial public offering. F1 · derivative.exercise_date: Represents shares of Class B common stock of Starboard Value Acquisition Corp. that converted into shares of Class A common stock of Cyxtera Technologies, Inc. (f/k/a Starboard Value Acquisition Corp.) (the "Issuer") in connection with the business combination between the Issuer, Mundo Merger Sub 1, Inc., Mundo Merger Sub 2, LLC, Cyxtera Technologies, Inc., and Mundo Holdings, Inc. F1 · derivative.expiration_date: Represents shares of Class B common stock of Starboard Value Acquisition Corp. that converted into shares of Class A common stock of Cyxtera Technologies, Inc. (f/k/a Starboard Value Acquisition Corp.) (the "Issuer") in connection with the business combination between the Issuer, Mundo Merger Sub 1, Inc., Mundo Merger Sub 2, LLC, Cyxtera Technologies, Inc., and Mundo Holdings, Inc. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 21:36 UTC | Cyxtera Technologies, Inc. CYXT · Entity 112555 | Exercise / conversionClass A Common Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031166 · doc4.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Class B common stock of Starboard Value Acquisition Corp. that converted into shares of Class A common stock of Cyxtera Technologies, Inc. (f/k/a Starboard Value Acquisition Corp.) (the "Issuer") in connection with the business combination between the Issuer, Mundo Merger Sub 1, Inc., Mundo Merger Sub 2, LLC, Cyxtera Technologies, Inc., and Mundo Holdings, Inc. F2 · shares: The reported number of shares reflect the receipt of 5,000 shares of Class B common stock of Starboard Value Acquisition Corp. as part of an in-kind dividend distributed to all holders of Class B common stock in connection with the closing of Starboard Value Acquisition Corp.'s initial public offering. F1 · price: Represents shares of Class B common stock of Starboard Value Acquisition Corp. that converted into shares of Class A common stock of Cyxtera Technologies, Inc. (f/k/a Starboard Value Acquisition Corp.) (the "Issuer") in connection with the business combination between the Issuer, Mundo Merger Sub 1, Inc., Mundo Merger Sub 2, LLC, Cyxtera Technologies, Inc., and Mundo Holdings, Inc. Read SEC document |
| May 24, 2021 Filed May 26, 2021 23:50 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCommon Stock, $0.001 par value | 75 | $40.35 | $3,026.25 |
DisclosureSEC source: 0000922423-21-000049 · form4.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150 Read SEC document |
| May 17, 2021 Filed May 20, 2021 00:37 UTC | PhenixFIN Corp PFX · Entity 6843 | PurchaseCommon Stock, $0.001 par value | 75 | $38.01 | $2,850.75 |
DisclosureSEC source: 0000922423-21-000039 · form4.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75 Read SEC document |
| October 23, 2020 Filed Oct 26, 2020 16:49 UTC | Barnes & Noble Education, Inc. BNED · Entity 5624 | GrantCommon Stock | 48,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001634117-20-000135 · wf-form4_160374533215339.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,781 F1 · shares: Grant of restricted shares vesting on October 23, 2021. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 19:50 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001209191-19-042723 · doc4.xml · derivative · entry 3 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F4 · price: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 19:50 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $5.34 | Not disclosed |
DisclosureSEC source: 0001209191-19-042723 · doc4.xml · derivative · entry 2 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F4 · price: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.exercise_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. F4 · derivative.expiration_date: Immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the Merger Consideration with respect to such shares. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 19:50 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | Disposition to issuerCommon Stock | 4,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-042723 · doc4.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2 · shares: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). F3 · shares: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards. F1 · price: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, and (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2 · price: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 17:58 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-19-035639 · doc4.xml · derivative · entry 2 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-05 F1 · derivative.exercise_date: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 17:58 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035639 · doc4.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Read SEC document |
| May 18, 2018 Filed May 22, 2018 17:39 UTC | ARATANA THERAPEUTICS, INC. PETX · Entity 155913 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001209191-18-032376 · doc4.xml · derivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: Vests in four equal installments on each of the first four anniversaries of the grant date, subject to continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 11:43 UTC | iMedia Brands, Inc. EVLV · Entity 12386 | PurchaseCommon Stock | 7,000 | $1.02 | $7,140.00 |
DisclosureSEC source: 0001209191-17-042452 · doc4.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,165 Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 12:25 UTC | iMedia Brands, Inc. EVLV · Entity 12386 | GrantCommon Stock | 59,090 | $1.10 | $64,999.00 |
DisclosureSEC source: 0001209191-17-040312 · doc4.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,165 F1 · shares: All shares vest on the day immediately preceding the Company's next annual meeting of shareholders. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 20:43 UTC | SITO MOBILE, LTD. SITO · Entity 147333 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001213900-17-006088 · f4053017robinson_sitomobile.xml · derivative · entry 3 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option became exercisable upon the date of grant. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 20:43 UTC | SITO MOBILE, LTD. SITO · Entity 147333 | Tax withholdingCommon Stock | 12,871 | $4.04 | $51,998.84 |
DisclosureSEC source: 0001213900-17-006088 · f4053017robinson_sitomobile.xml · nonDerivative · entry 2 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,129 F1 · kind: Represents a "net exercise" of outstanding stock options. The reporting person received 7,129 shares of common stock on the net exercise of an option to purchase 20,000 shares of common stock. The reporting person forfeited 12,871 shares of common stock underlying the option in payment of the exercise price, based on the market price of SITO common stock on May 30, 2017 of $4.04. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 20:43 UTC | SITO MOBILE, LTD. SITO · Entity 147333 | Exercise / conversionCommon Stock | 20,000 | $2.60 | $52,000.00 |
DisclosureSEC source: 0001213900-17-006088 · f4053017robinson_sitomobile.xml · nonDerivative · entry 1 ROBINSON LOWELL W · CIK 0001244216 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.